The type I interferon (IFN-I)-inducible human restriction factor TRIM5α inhibits the infection of 17 human cells by specific nonhuman retroviruses, such as N-MLV and EIAV, but does not 18 generally target HIV-1. However, the introduction of two aminoacid substitutions, R332G and 19 R355G, in the human TRIM5α (huTRIM5α) domain responsible for retroviral capsid recognition 20 leads to efficient HIV-1 restriction. Using a DNA transfection-based CRISPR-Cas9 genome 21 editing protocol, we successfully mutated TRIM5 to its HIV-1-restrictive version by homology-22 directed repair (HDR) in HEK293T cells. Nine clones bearing at least one HDR-edited TRIM5 23 allele containing both mutations were isolated (5.6% overall efficiency), whereas another one 24 contained only the R332G mutation. Of concern, several of these HDR-edited clones contained 25 on-target undesired mutations, and none had all the alleles corrected. We observed a lack of 26 HIV-1 restriction in the cell clones generated, even when cells were stimulated with IFN-I prior 27 to infection. This, however, was partly explained by the unexpectedly low potential for TRIM5α-28 mediated restriction activity in this cell line. Our study demonstrates the feasibility of editing the 29 TRIM5 gene to in human cells and identifies the main challenges to be addressed in order to use 30 this approach to confer protection from HIV-1. 31
Introduction 32
Viruses are obligate parasites whose success at infecting a host cell typically requires evasion 33 from antiviral factors. In mammals, many cellular antiviral factors that can potentially interfere destabilization of the capsid core [7] , proteasomal degradation of some core components [8] and 48 sequestration of the viral particle in TRIM5α cytoplasmic bodies [9] . huTRIM5α generally has 49 little-to-no activity against HIV-1, but efficiently inhibits the infectivity of the nonhuman 50 gammaretrovirus "N-tropic" murine leukemia virus (N-MLV) as well as the nonhuman lentivirus 51 equine infectious anemia virus (EIAV) [10] . Those two viruses are typically inhibited ~10-fold 52 (EIAV) and ~100-fold (N-MLV) by endogenous huTRIM5α, with some variation depending on 53 the cellular context. 54 Several groups, including ours, have attempted to harness the antiviral power of TRIM5α in 55 order to interfere with HIV-1. This virus is efficiently restricted (~100-fold) by some orthologs 56 of TRIM5α found in Old World monkeys such as the Rhesus macaque TRIM5α (rhTRIM5α) [4] . 57 However, significant sequence variation between the human and macaque orthologs preclude the 58 possibility of using the latter one in gene therapy approaches, as this would increase the risk to 59 elicit an immune response against the transgene in patients. Thus, all the studies have consisted 60 in over-expressing versions of huTRIM5α designed to target HIV-1 through modifications in the 61 SPRY domain. Some of the TRIM5α variants used were chimeric products containing small 62 regions of rhTRIM5α in the SPRY [11, 12] . Other teams mapped with further precision the HIV- 63 1 restriction determinants in rhTRIM5α that were absent in huTRIM5α, leading to the discovery 64 that mutating the Arg332 residue in huTRIM5α was sufficient to inhibit HIV-1. Although initial 65 observations [13, 14] raised the hope that single mutations at this position might inhibit HIV-1 as 66 efficiently as rhTRIM5α did, later work made it clear that this was not the case [15] . 67 Our laboratory explored a different approach: generating libraries of TRIM5α SPRY mutants 68 then applying a functional screen to isolate mutants that conferred HIV-1 restriction [16, 17] . 69 These studies identified mutations at Arg335 inhibiting HIV-1 by 5-to 10-fold. When we 70 combined a mutation at Arg335 (R335G) with one at Arg332 (R332G), we obtained restriction 71 levels that were higher than with either of the single mutants [16, 17] . Although not quite as 72 restrictive as rhTRIM5α, R332G-R335G huTRIM5α efficiently inhibited the propagation of a 73 highly pathogenic strain of HIV-1, and cells expressing the transgene had a survival advantage 74 over unmodified cells [15] .
75
Although R332G-R335G huTRIM5α is considered a prime candidate in HIV-1 gene therapy 76 approaches to inhibit HIV-1, using lentiviral vectors to overexpress it in human cells is not 77 without caveats. Indeed, the physiological effects of TRIM5α overexpression in vivo are not 78 clear, considering that it is involved in innate immune responses [18, 19] and possibly in 79 autophagy [20] . In addition, the genotoxicity of lentiviral vectors integrating in the human 80 genome is still poorly predictable. In the longer term, it would thus be desirable to be able to 81 introduce mutations in the endogenous human TRIM5 by genome editing. Here we describe the 82 use of Clustered Regularly Interspaced Short Palindromic Repeats with Cas9 (CRISPR-Cas9) 83 and of a single-stranded homology-directed repair (HDR) donor DNA to successfully mutate 84 Arg332 and Arg335 in a human cell line.
85

Results
86
Strategy for the mutagenesis of TRIM5 by HDR. Human TRIM5 is found on chromosome 87 11p15.4 and the region of the gene encoding the SPRY domain is present in exon 8 ( Fig 1A) . We 88 searched for DNA loci close to the codons for Arg332 and Arg335 that would be potential 89 targets for CRISPR-Cas9-mediated double-strand cleavage. CRISPR guide RNAs (gRNAs) were 90 designed for the 3 potential target sites that were nearest to the two codons to be mutated (Fig   91   1B ). CRISPR plasmids expressing Cas9 along with one of the designed gRNAs were transfected 92 in human embryonic kidney 293T cells (HEK293T), and a Surveyor assay was performed to test 93 the capacity of the three gRNAs to target the endogenous TRIM5 gene. Results showed that all 94 three gRNAs were competent ( Fig 1B) . Because gRNA1 induces a cleavage that is closest to the 95 targeted codons (right before the first nt of Arg332), the rest of the project was carried out with (depicted in the same orientation as the TRIM5 mRNA for clarity purposes). In addition to 100 the mutations substituting arginine residues into glycine at positions 332 and 335, we included 4 101 silent mutations in the region recognized by the gRNA and 1 more silent mutation in the 102 protospacer adjacent motif (PAM), amounting to a total of 7 substitutions expected to prevent the 103 cleavage of the donor DNA by Cas9. One of the mutations also created a HaeIII cut site for 104 convenient downstream screening of the cell clones obtained. were then isolated by limiting dilution. We screened 161 clones at random for the presence of 120 HDR-modified alleles by specifically amplifying the mutated TRIM5 sequence using a primer 121 whose sequence is indicated in Fig 1C. As shown in Fig S1, 14 clones showed a positive signal 122 (of varying intensity) in this assay. One of the clones, F2X, yielded a band whose size seemed 123 bigger compared to another positive clone (C8) analyzed on the same gel. All these clones 124 (minus A12, which did not survive) were re-analyzed using the same specific PCR assay and 125 also using a second assay in which the targeted region is amplified and then digested by HaeIII, 126 which cuts at a site created by one of the silent mutations (see Fig 1C) . In the latter assay, 127 amplification was done using primers that bind outside the 200 nts corresponding to the donor 128 ssODN in order to insure that the ssODN was not inadvertently detected. Figure 2 shows a 129 positive signal for 10 of these clones in both assays. The three remaining clones were negative in 130 both assays. 
191
Examination of the TRIM5 alleles not modified by HDR in these cell clones revealed that they 192 showed clear signs of NHEJ-induced mutations, i.e. indels at the cleavage site. 8 alleles had an A 193 inserted at the cleavage site, whereas one of the F2X alleles had a TT inserted at the same locus.
194
The A insertion was so prevalent that in half of the clones (C1, C10, D11, F2, F11), 2 of the 3 195 TRIM5 copies were mutated by NHEJ leading to this particular mutation. Although the nature of 196 NHEJ-directed mutations is known to vary widely depending on the gRNA used [26] , such +1 as the huTRIM5α-sensitive murine oncoretrovirus N-MLV and its huTRIM5α-insensitive 214 counterpart B-MLV. In previous studies, we found that compared to the WT huTRIM5α, the 215 R332G-R335G mutant restricted SIVmac and N-MLV at slightly higher levels, whereas EIAV 216 and B-MLV were not affected [16] . Therefore, if HIV-1 was specifically restricted by a TRIM5α 217 mutant in a given cell clone, we would expect the EIAV and B-MLV vectors to be restriction-218 negative controls. However, the infectivity profiles obtained in the various cell populations were 219 similar. In particular, C10 was the cell clone least permissive to HIV-1 NL-GFP ( Fig 4A) , but it was 220 also poorly permissive toward infection by the 4 other retroviral vectors (Fig 4B-E) . Likewise,
221
C1 was relatively more susceptible to infection by HIV-1 NL-GFP , but these cells were also more 222 permissive to infection with the other 4 retroviral vectors. Of interest, however, was the fact that restriction levels that were closer to 3-fold ( Fig S2) . We conclude that the potential for TRIM5α-272 mediated restriction is abnormally low in the HEK293T cell line used here.
273
Discussion
274
To our knowledge, this is the first attempt at using genome editing to mutate a restriction factor 275 with the aim of conferring an innate antiviral function in human cells. Although we did not which an allele had been modified by HDR. It is predicted that the SPRY-truncated TRIM5α 281 proteins resulting from the presence of indels will interact with the full-length TRIM5α and will 282 interfere with its targeting of incoming retroviruses, similar to the activity of natural, shorter 283 TRIM5 isoforms [5, 33] . We did not investigate any further the reasons behind the lack of 284 restriction in this particular cell line, as we are now focusing on editing TRIM5 in lymphoid and 285 myeloid cells. However, future research will need to address the difficulty of achieving bi-allelic 286 HDR-mediated editing. Recent technological advances, including the development of a marker-287 free system to enrich cells in which HDR occurred [34] , are likely to enhance editing efficiency 288 as well as bi-allelic editing. Also affecting the therapeutic potential of TRIM5 editing is the 289 occurrence of unwanted on-target indels, in 3 out of 9 alleles bearing the two therapeutic 290 mutations in this study. Therefore, future studies will also need to identify the determinants of 291 fidelity in HDR repair in order to minimize the incidence of such indels. Despite the absence of 292 an antiviral effect, this study paves the way and identifies the pitfalls toward the goal of efficient, 293 bi-allelic, scarless TRIM5 editing in order to confer HIV-1 resistance in human cells. proteinase K-containing water as recommended by the manufacturer. Lysis was allowed to 336 proceed overnight at 55˚C followed by heating at 85˚C for 90 min to deactivate proteinase K.
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For the specific PCR-based screening, 5 µl of the lysed cells were subjected to PCR using We are grateful to Feng Zhang (Broad Institute, Cambridge, USA) for sharing reagents. We 
